This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts

This study is not yet open for participant recruitment.
See Contacts and Locations
Verified November 2015 by Roxall Medizin
Sponsor:
Information provided by (Responsible Party):
Roxall Medizin
ClinicalTrials.gov Identifier:
NCT01012752
First received: November 11, 2009
Last updated: November 2, 2015
Last verified: November 2015
  Purpose
This trial is performed to evaluate the safety and clinical efficacy of subcutaneous specific immunotherapy in patients suffering from seasonal allergic rhinitis/rhinoconjunctivitis.

Condition Intervention Phase
Allergic Rhinitis Allergic Conjunctivitis Biological: modified allergen extract Biological: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-Blind, Placebo-Controlled Study With a Modified Allergen Extract for Specific Immunotherapy in Patients With Seasonal Allergic Rhinitis/Rhinoconjunctivitis

Further study details as provided by Roxall Medizin:

Primary Outcome Measures:
  • Symptom and medication score [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Safety of the treatment [ Time Frame: 1 year ]
  • Documentation of adverse events [ Time Frame: 1 year ]
  • Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) [ Time Frame: 1 year ]
  • Clinical global improvement [ Time Frame: 1 year ]

Estimated Enrollment: 150
Study Start Date: October 2016
Estimated Study Completion Date: October 2017
Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: modified allergen extract Biological: modified allergen extract
subcutaneous injections
Placebo Comparator: Placebo Biological: Placebo
subcutaneous injections

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Positive history of allergen specific allergic rhinitis/rhinoconjunctivitis
  • Positive screening skin prick test (wheal diameter > 3 mm)
  • Compliance and ability of the patient to complete a Diary Card for self-evaluating of the symptoms and antisymptomatic medication
  • Signed and dated patient´s Informed Consent,

Exclusion Criteria:

  • Previous immunotherapy within the last 3 years,
  • Simultaneous participation in other clinical trials,
  • Other reasons contra-indicating an inclusion into the trial according to the investigator´s estimation (e.g. poor compliance),
  • Auto-immune disorders,
  • Severe chronic inflammatory diseases,
  • Malignancy,
  • Alcohol abuse,
  • Existing or intended pregnancy, lactation and/or lack of adequate contraceptive protection,
  • Treatment with beta-blockers (incl. local application) and/or other contra-indicated drugs.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01012752

Contacts
Contact: Roxall Medizin +49408972520

Locations
Germany
Hamburg, Germany
Sponsors and Collaborators
Roxall Medizin
  More Information

Responsible Party: Roxall Medizin
ClinicalTrials.gov Identifier: NCT01012752     History of Changes
Other Study ID Numbers: SBC-2009-003B
Study First Received: November 11, 2009
Last Updated: November 2, 2015

Additional relevant MeSH terms:
Conjunctivitis
Conjunctivitis, Allergic
Rhinitis, Allergic
Rhinitis
Nose Diseases
Respiratory Tract Diseases
Respiratory Hypersensitivity
Otorhinolaryngologic Diseases
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Respiratory Tract Infections
Conjunctival Diseases
Eye Diseases

ClinicalTrials.gov processed this record on June 28, 2017